Salivary CD44 and Total Protein Levels to Detect Risk for Oral and Oropharyngeal Cancer Recurrence: A Nonrandomized Clinical Trial.

ABSTRACT:

Importance

Oral and oropharyngeal cancer have low survival rates, and incidence continues to increase.

Objective

To determine whether soluble CD44 and total protein (TP) are useful for monitoring head and neck cancer recurrence, either used in a point-of-care (POC) test or as individual laboratory-based biomarkers.

Design, setting, and participants

This multi-institutional nonrandomized clinical trial testing a novel diagnostic/screening assay took place across the University of California, San Diego; Johns Hopkins University; the Greater Baltimore Medical Center; New York University; and the San Diego Veterans Affairs Hospital. Patients with newly biopsy-proven, untreated oral cavity and oropharyngeal cancer were enrolled. Patients were enrolled April 2017 to April 2

SUBMITTER: Franzmann EJ 

PROVIDER: S-EPMC11327900 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature